Risk factors in the pathogenesis of invasive group A streptococcal infections: Role of protective humoral immunity

Infection and Immunity

Volumn 67, Issue 4, 1999, Pages 1871-1877

  Basma, Hesham ^a,b   Norrby Teglund, Anna ^a   Guedez, Yajaira ^b   McGeer, Allison ^c   Low, Donald E ^c   El Ahmedy, Omar ^a   Schwartz, Benjamin ^d   Kotb, Malak ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ARTICLE; BACTERIAL VIRULENCE; CLINICAL ARTICLE; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; INFECTION PREVENTION; INFECTION RISK; PRIORITY JOURNAL; RISK FACTOR; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

EID: 0033040119     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.4.1871-1877.1999     Document Type: Article

References (53)

1. Alouf, J. E., H. Knoll, and W. Kohler. 1991. The family of mitogenic, shock-inducing and superantigenic toxins from staphylococci and streptococci, p. 367-414. In J. E. Alouf and J. H. Freer (ed.), Sourcebook of bacterial protein toxins. Academic Press, London, United Kingdom.
2. Basma, H., A. Norrby-Teglund, D. E. Low, A. McGeer, O. El-Ahmady, and M. Kotb. 1998. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulin G (IVIG): potential impact on the clinical efficacy of IVIG in severe invasive group A streptococcal infections. Infect. Immun. 66:2279-2283.
3. Beachey, E. H., and J. M. Seyer. 1982. Primary structure and immunochemistry of group A streptococcal M proteins. Semin. Infect. Dis. 4:401-410.
4. Bisno, A., and D. Stevens. 1996. Streptococcal infections of skin and soft tissues. N. Engl. J. Med. 334:240-245.
5. Campbell, J. R., C. A. Arango, J. A. Garcia-Prats, and C. J. Baker. 1996. An outbreak of M serotype 1 group A streptococcus in a neonatal intensive care unit. J. Pediatr. 129:396-402.
6. Chatellier et al. Unpublished data.
7. Chaussee, M. S., J. Liu, D. L. Stevens, and J. J. Ferretti. 1996. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J. Infect Dis. 173:901-908.
8. Chelsom, J., A. Halstensen, T. Haga, and A. Hoiby. 1994. Necrotizing fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 344:1111-1115.
9. Cockerill, F. R. R., K. L. MacDonald, and R. L. Thompson. 1997. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 277:38-43.
10. Cone, L. A., D. R. Woodard, P. M. Schlievert, and G. S. Tomory. 1987. Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N. Engl. J. Med. 317:146-149.
11. Davies, H. D., A. McGeer, B. Schwartz, K. Green, D. Cann, A. E. Simor, D. E. Low, the Ontario Group A Streptococcal Study Group. 1996. Invasive group A streptococcal infections in Ontario, Canada. N. Engl. J. Med. 335:547-554.
12. de Malmanche, S., and D. Martin. 1994. Protective immunity to the group A streptococcus may be only strain specific. Med. Microbiol. Immunol. 183: 299-306.
13. Demers, B., D. E. Low, A. E. Simor, H. Vellend, F. Jamieson, S. Walmsley, K. Green, and C. Krishnan. 1991. Severe group A streptococcal disease -southern Ontario. Ontario Streptococcal Study Group. Can. Dis. Weekly Rep. 17:192-194.
14. Demers, B., A.-E. Simor, H. Vellend, P. M. Schlievert, S. Byrne, F. Jamieson, S. Walmsley, and D. E. Low. 1993. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin. Infect. Dis. 16:792-800.
15. Ferrieri, P. 1991. Microbiological features of current virulent strains of group A streptococci. Pediatr. Infect. Dis. J. 10(Suppl.):S20-S24.
16. Fischer, G. W., S. R. Wilson, and K. W. Hunter. 1982. Functional characteristics of a modified immunoglobulin preparation for intravenous administration: summary of studies of opsonic and protective activity against group B streptococci. J. Clin. Immunol. 2:31-35.
17. Fischetti, V. A. 1991. Streptococcal M protein. Sci. Am. 264:58-65.
18. Gaworzewska, E., and G. Colman. 1988. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol. Infect. 100:257-269.
19. Haanes-Fritz, E., W. Kraus, V. Burdett, J. B. Dale, E. H. Beachey, and P. P. Cleary. 1988. Comparison of the leader sequences of 4 group A streptococcal M protein genes. Nucleic Acid Res. 10:4667-4677.
20. Hoge, C. W., B. Schwartz, D. F. Talkington, R. F. Breiman, E. M. MacNeill, and S. J. Englender. 1993. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 269:384-389.
21. Hoiby, E. A. 1990. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand. J. Infect. Dis. 22:421-429.
22. Holm, S. E., A. Norrby, A. M. Bergholm, and M. Norgren. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J. Infect. Dis. 166:31-37.
23. Kamezawa, Y., T. Nakahara, S. Nakano, Y. Abe, J. Nozaki-Renard, and T. Isono. 1997. Streptococcal mitogenic exotoxin Z. a novel acidic superantigenic toxin. Infect. Immun. 65:3828-3833.
24. Kaul, R., A. McGeer, D. E. Low, K. Green, and B. Schwartz. 1997. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am. J. Med. 103:18-24.
25. Kiska, D. L., B. Thiede, J. Caracciolo, M. Jordan, D. Johnson, E. L. Kaplan, R. P. Gruninger, J. A. Lohr, P. H. Gilligan, and F. W. Denny, Jr. 1997. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J. Infect. Dis. 176:992-1000.
26. Kohler, W. 1992. Epidemiology and pathogenesis of streptococcal infection. Immun. Infekt. 20:92-98.
27. Kotb, M. 1995. Bacterial exotoxins as superantigens. Clin. Microbiol. Rev. 8:411-426.
28. Kotb, M. 1992. Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr. Opin. Infect. Dis. 5:364-374.
29. Kotb, M., H. Ohnishi, G. Majumdar, S. Hackett, A. Bryant, G. Higgins, and D. Stevens. 1993. Temporal relationship of cytokine release by peripheral blood mononuclear cells stimulated by the streptococcal superantigen pep M5. Infect. Immun. 61:1194-1201.
30. Kraus, W., J. B. Dale, and E. H. Beachey. 1990. Identification of an epitope of type 1 streptococcal M protein that is shared with a 43-kD protein of human myocardium and renal glomeruli. J. Immunol. 145:4089-4093.
31. Kuwahata, M., H. Imanaka, S. Takei, and K. Masuda. 1996. Age-related occurrence of inhibitory antibodies to streptococcal pyrogenic superantigens. Acta Paediatr. Jpn. 38:1-7.
32. Low, D. E., B. Schwartz, and A. McGeer. 1997. The reemergence of severe group A streptococcal disease: an evolutionary perspective, p. 93-123. In W. M. Scheld, D. Armston, and J. M. Hughes (ed.), Emerging infections I. American Society for Microbiology, Washington, D.C.
33. Martin, P. R., and E. A. Hoiby. 1990. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand. J. Infect. Dis. 22:421-429.
34. Mollick, J., G. Miller, J. Musser, R. Cook, D. Grossman, and R. Rich. 1993. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J. Clin. Invest. 92:710-719.
35. Muotiala, A., H. Saxen, and J. Vuopio-Varkila. 1997. Group A streptococcal outbreak of perinatal infection in a day-care centre. Adv. Exp. Med. Biol. 418:211-215.
36. Musser, J. M., V. Kapur, S. Kanjilal, U. Shah, D. M. Musher, N. L. Barg, K. H. Johnston, P. M. Schlievert, J. Henrichsen, D. Gerlach, et al. 1993. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin). J. Infect. Dis. 167:337-346.
37. Norgren, M., A. Norrby, and S. E. Holm. 1992. Genetic diversity in TIMI group A streptococci in relation to clinical outcome of infection. J. Infect. Dis. 166:1014-1020.
38. Norrby-Teglund, A., H. Basma, D. E. Low, A. McGeer, and M. Kotb. 1998. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G (IVIG): implications for therapeutic efficacy. J. Clin. Infect. Dis. 26:631-641.
39. Norrby-Teglund, A., R. Kaul, D. E. Low, A. McGeer, J. P. Andersson, U. G. Andersson, and M. Kotb. 1996. Evidence for the presence of streptococcal superantigen neutralizing antibodies in normal polyspecific immunoglobulin G. Infect. Immun. 64:5395-5398.
40. Norrby-Teglund, A., R. Kaul, D. E. Low, A. McGeer, J. P. Andersson, U. G. Andersson, and M. Kotb. 1996. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen induced T cell proliferation and cytokine production. J. Immunol. 156:3057-3064.
41. Norrby-Teglund, A., R. Lustig, and M. Koth. 1997. Differential induction of Th1 versus Th2 cytokines by group A. Infect. Immun. 65:5209-5215.
42. Norrby-Teglund, A., M. Norgren, S. E. Holm, U. Andersson, and J. Andersson. 1994. Similar cytokine induction profiles of a novel streptococcal exotoxin, MF, and pyrogenic exotoxins A and B. Infect. Immun. 62:3731-3738.
43. Norrby-Teglund, A., K. Pauksen, S. E. Holm, and M. Norgren. 1994. Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J. Infect. Dis. 170:585-591.
44. Peterson, C. L., D. J. Vugia, H. B. Meyers, S. M. Chao, J. Vogt, J. Lanson, P. A. Brunell, K. S. Kim, and L. Mascola. 1996. Risk factors for invasive group A streptococcal infections in children with varicella: a case-control study. Pediatr. Infect. Dis. J. 15:151-156.
45. Schlievert, P. M. 1993. Role of superantigens in human diseases. J. Infect. Dis. 167:997-1002.
46. Schwartz, B., J. A. Elliott, J. C. Butler, P. A. Simon, B. L. Jameson, G. E. Welch, and R. R. Facklam. 1992. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin. Infect. Dis. 15:277-284.
47. Shanley, T., D. Schrier, V. Kapur, M. Kehoe, and J. Musser. 1996. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect. Immun. 64:870-877.
48. Stanley, J., M. Desai, A. Efstratiou, and R. George. 1997. High-resolution genotyping of Streptococcus pyogenes. Application to outbreak studies and population genetics. Adv. Exp. Med. Biol. 418:313-316.
49. Stevens, D. L. 1992. Invasive group A streptococcus infections. Clin. Infect. Dis. 14:2-13.
50. Stevens, D. L., M. H. Tanner, J. Winship, R. Swarts, K. M. Ries, P. M. Schlievert, and E. Kaplan. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321:1-7.
51. Sullivan, G. W., and G. L. Mandell. 1991. The role of cytokines in infection. Curr. Opin. Infect. Dis. 4:344-349.
52. Watanabe-Ohnishi, R., D. E. Low, A. McGeer, D. L. Stevens, P. M. Schlievert, B. Schwartz, B. Kreiwwirth, and M. Kotb. 1994. Selective depletion of Vβ-Bearing T cells in patients with invasive group A streptococcal disease and streptococcal toxic shock syndrome: implications for a novel superantigen. J. Infect. Dis. 171:74-84.
53. Working Group on Severe Streptococcal Infections. 1993. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 269:390-391.